Cerebrolysin enhances functional recovery following focal cerebral infarction in rats

Restorative Neurology and Neuroscience

Volumn 25, Issue 1, 2007, Pages 25-31

  Ren, Jingmei ^a   Sietsma, Dana ^a   Qiu, Shumei ^a   Moessler, Herbert ^b   Finklestein, Seth P ^a,c  

^a Viacord Inc   (United States)

^b Research Initiative Ebewe   (Austria)

^c Biotrofix Inc   (United States)

Author keywords

Cerebrolysin; Rats; Stroke recovery

Indexed keywords

CEREBROLYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY EQUILIBRIUM; BODY WEIGHT; BRAIN INFARCTION; BRAIN INFARCTION SIZE; CONTROLLED STUDY; CONVALESCENCE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; FORELIMB; LIMB MOVEMENT; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION; STROKE; TREATMENT DURATION; TREATMENT OUTCOME;

AMINO ACIDS; ANALYSIS OF VARIANCE; ANIMALS; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FUNCTIONAL LATERALITY; MALE; NEUROPROTECTIVE AGENTS; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; TIME FACTORS;

EID: 34247326556     PISSN: 09226028     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Satou, T., Itoh, T., Tamai, Y., Ohde, H., Anderson, A. J. & Hashimoto, S. (2000). Neurotrophic effects of FPF-1070 (Cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks, J. Neural Transm. 107, 1253-1262.
2. Hartbauer, M., Hutter-Paier, B., Skofitsch, G. & Windisch, M. (2001). Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons, J. Neural Transm. 108, 459-473.
3. Hutter-Paier, B., Grygar, E. & Windisch, M. (1996). Death of cultured telencephaolon neurons induced by glutamate is reduced by the peptide derivative Cerebrolysin, J Neural Transm 47, 267-273.
4. Veinbergs, I., Mante, M., Mallory, M. & Masliah, E. (2000). Neurotrophic effects of Cerebrolysin in animals models of excitotoxicity, J Neural Transm 59, 273-280.
5. Gonzalez, M. E., Francis, L. & Castellano, O. (1998). Antioxidant systemic effect of short-term Cerebrolysin administration, J Neural Transm 53, 333-341.
6. Wronski, R., Tompa, B., Hutter-Paier, B., Crailsheim, K., Friedrich, B. & Windisch, M. (2000). Inhibitory effect of a brain derived peptide preparation on the intracellular calcium Ca++-dependent protease, calpain, J Neural Transm 107, 145-157.
7. Tatebayashi, Y., Lee, M. H., Li, L., Iqbal, K. & Grundke-Iqbal, I. (2003). The dentate gyrus neurogenesis. A therapeutic target for Alzheimer's disease, Acta Neuropathol 2003, 225-232.
8. Schwab, M., Schaller, R., Bauer, R. & Zweiner, U. (1997). Morphofunctional effects of moderate forebrain ischaemia combined with short-term hypoxia in rats - protective effects of Cerebrolysin, Exp Toxic Pathol 49, 29-37.
9. Schwab, M., Antonow-Schlorke, I., Zwiener, U. & Bauer, R. (1998). Brain derived peptides reduce the size of cerebral infarction and loss of MAP-2 immunoreactivity after focal ischaemia in rats, J Neural Transm 53, 299-311.
10. Frey, W. (2002). Tratment of stroke with intravenous and intranasal Cerebrolysin, Ebewe Pharma Research Report 1-22.
11. Gusev, E. I., Burd, G. S., Guekht, A. B., Skvortsova, V. I., Bogomolova, M. A., Selikhova, M.V., et al. (1994). Cerebrolysin action on brain function in acute hemispheric ischemic stroke and in early convalescence: cliniconeurophysiological study, ZH Neuropathol Psikhiatr Korsakow 94, 9-13.
12. Barolin, G. S., Koppi, S. & Kapeller, E. (1996). Old and new aspects of stroke treatment with emphasis on metabolically active medication and rehabilitative outcome, EuroRehab 3, 135-143.
13. Haffner, Z., Gmeinbauer, R. & Moessler, H. (2001). A randomized, double-blind, placebo-controlled trial with Cerebrolysin in acute ischaemic stroke, Cerebrovasc Dis 11, 76.
14. Ladurner, G., Kalvach, P., Moessler, H. & Group, C.S. (2005). Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial, J Neural Transm 112, 415-428.
15. Ren, J.M. & Finklestein, S. P. (2005). Growth factor treatment of stroke, Current Drug Targets - CNS and Neurological Disorders 4, 119-123.
16. Koketsu, N., Berlove, D. J., Moskowitz, M. A., Kowall, N. W., Caday, C. G. & Finklestein, S. P. (1994). Pretreatment with intraventricular basic fibroblast growth factor (bFGF) decreases infarct size following focal cerebral ischemia in rats, Ann Neurol 35, 451-457.
17. Ren, J. M. & Finklestein, S. P. (1997). Time dependence of infarct reduction by intravenous basic fibroblast growth factor (bFGF) following focal cerebral ischemia in rats, Eur J Pharmacol 327, 11-16.
18. Ay, I., Sugimori, H. & Finklestein, S. P. (2001). Intravenous basic fibroblast growth factor (bFGF) decreases DNA fragmentation and prevents downregulation of Bcl-2 expression in the ischemic brain following middle cerebral artery occlusion in rats, Mol. Brain Research 87, 71-80.
19. Kawamata, T., Dietrich, W. D., Schallert, T., Gotts, J. E., Cocke, R. R., Benowitz, L.I., et al. (1997). Intracisternal basic fibroblast growth factor (bFGF) enhances functional recovery and upregulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction, Proc Natl Acad Sci 94, 8179-8184.
20. Wada, K., Sugimori, H., Bhide, P.B., Moskowtiz, M. A. & Finklestein, S. P. (2003). Effect of basic fibroblast growth factor treatment on brain progenitor cells after permanent focal ischemia in rats, Stroke 34, 2722-2728.
21. Kawamata, T., Ren, J. M., Cha, C. H. & Finklestein, S. P. (1999). Intracisternal antisense oligonucleotide to growth associated protein-43 (GAP-43) blocks the recovery-promoting effects of basic fibroblast growth factor (bFGF) after focal stroke, Exp Neurol 158, 89-96.
22. Swanson, R. A., Morton, M. T., Tsao-Wu, G., Savalos, R. A., Davidson, C. & Sharp, F. R. (1990). A semiautomated method for measuring brain infarct volume, J Cereb Blood Flow Metab 10, 290-293.
23. Ren, J., Kaplan, P. L., Charette, M. F., Speller, H. & Finklestein, S. P. (2000). Time window of intracisternal osteogenic protein-1 in enhancing functional recovery after stroke, Neuropharmacology 39, 860-865.
24. Chen, H., Tung, Y., Lee, M. H., Li, L., Iqbal, K. & Grundke-Iqbal, I., Neurotrophic factors counteract the elevated FGF-2-induced inhibition of neurogenesis, Neurobiol Aging (Submitted).
25. Fisher, M., Meadows, M. -E., Do, T., Weise, J., Trubetskoy, V., Charette, M. & Finklestein, S. P. (1995). Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats, J Cereb Blood Flow Metab 15, 953-959.
26. Lo, E. H., Singhal, A. B., Torchilin, V.P. & Abbott, N. J. (2001). Drug delivery to damaged brain, Brain Research Rev. 38, 140-148.
27. Bae, C. -Y., Cho, C. -Y., Cho, K., Oh, B. H., Choi, G. K., Lee, H. S., et al., (2000). A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease, J Am Ger Soc 48, 1566-1571.
28. Ruether, E., Husmann, R., Kinzler, E., Diabl, E., Lingler, E., Spatt, J., et al. (2001). A 28 week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease, Int Clin Pschopharm 16, 253-263.
29. Panisset, M., Gauthier, S., Moessler, H., Windisch, M. & Group, C. S. (2002). Cerebrolysin in Alzheimer's Disease: A randomized, double-blind, placebo-controlled trial with a neurotrophic agent, J Neural Transm 109, 1089-1104.